Patent application number | Description | Published |
20110083108 | PROVIDING USER INTERFACE FEEDBACK REGARDING CURSOR POSITION ON A DISPLAY SCREEN - Disclosed herein are systems and methods for providing user interface feedback regarding a cursor position on a display screen. A user may use a suitable input device for controlling a cursor in a computing environment. The displayed objects may provide feedback regarding the cursor's position. Particularly, a position of the cursor may be compared to an object's position for determining whether the cursor is positioned on the display screen at the same position as a portion of the object or within a predetermined distance of the portion of the object. In response to determining the cursor is positioned on the display screen at the same position as the portion of the object or within the predetermined distance of the portion of the object, an appearance of the portion of the object may be altered, such as, for example, brightness or color of the object portion. | 04-07-2011 |
20110182481 | VOICE-BODY IDENTITY CORRELATION - A system and method are disclosed for tracking image and audio data over time to automatically identify a person based on a correlation of their voice with their body in a multi-user game or multimedia setting. | 07-28-2011 |
20110184735 | SPEECH RECOGNITION ANALYSIS VIA IDENTIFICATION INFORMATION - Embodiments are disclosed that relate to the use of identity information to help avoid the occurrence of false positive speech recognition events in a speech recognition system. One embodiment provides a method comprising receiving speech recognition data comprising a recognized speech segment, acoustic locational data related to a location of origin of the recognized speech segment as determined via signals from the microphone array, and confidence data comprising a recognition confidence value, and also receiving image data comprising visual locational information related to a location of each person in an image. The acoustic locational data is compared to the visual locational data to determine whether the recognized speech segment originated from a person in the field of view of the image sensor, and the confidence data is adjusted depending on this determination. | 07-28-2011 |
20110193939 | PHYSICAL INTERACTION ZONE FOR GESTURE-BASED USER INTERFACES - In a motion capture system having a depth camera, a physical interaction zone of a user is defined based on a size of the user and other factors. The zone is a volume in which the user performs hand gestures to provide inputs to an application. The shape and location of the zone can be customized for the user. The zone is anchored to the user so that the gestures can be performed from any location in the field of view. Also, the zone is kept between the user and the depth camera even as the user rotates his or her body so that the user is not facing the camera. A display provides feedback based on a mapping from a coordinate system of the zone to a coordinate system of the display. The user can move a cursor on the display or control an avatar. | 08-11-2011 |
20110197161 | HANDLES INTERACTIONS FOR HUMAN-COMPUTER INTERFACE - A system is disclosed for providing on-screen graphical handles to control interaction between a user and on-screen objects. A handle defines what actions a user may perform on the object, such as for example scrolling through a textual or graphical navigation menu. Affordances are provided to guide the user through the process of interacting with a handle. | 08-11-2011 |
20110279368 | INFERRING USER INTENT TO ENGAGE A MOTION CAPTURE SYSTEM - Techniques are provided for inferring a user's intent to interact with an application run by a motion capture system. Deliberate user gestures to interact with the motion capture system are disambiguated from unrelated user motions within the system's field of view. An algorithm may be used to determine the user's aggregated level of intent to engage the system. Parameters in the algorithm may include posture and motion of the user's body, as well as the state of the system. The system may develop a skeletal model to determine the various parameters. If the system determines that the parameters strongly indicate an intent to engage the system, then the system may react quickly. However, if the parameters only weakly indicate an intent to engage the system, it may take longer for the user to engage the system. | 11-17-2011 |
20110289455 | Gestures And Gesture Recognition For Manipulating A User-Interface - Symbolic gestures and associated recognition technology are provided for controlling a system user-interface, such as that provided by the operating system of a general computing system or multimedia console. The symbolic gesture movements in mid-air are performed by a user with or without the aid of an input device. A capture device is provided to generate depth images for three-dimensional representation of a capture area including a human target. The human target is tracked using skeletal mapping to capture the mid-air motion of the user. The skeletal mapping data is used to identify movements corresponding to pre-defined gestures using gesture filters that set forth parameters for determining when a target's movement indicates a viable gesture. When a gesture is detected, one or more pre-defined user-interface control actions are performed. | 11-24-2011 |
20110289456 | Gestures And Gesture Modifiers For Manipulating A User-Interface - Gesture modifiers are provided for modifying and enhancing the control of a user-interface such as that provided by an operating system or application of a general computing system or multimedia console. Symbolic gesture movements are performed by a user in mid-air. A capture device generates depth images and a three-dimensional representation of a capture area including a human target. The human target is tracked using skeletal mapping to capture the mid-air motion of the user. Skeletal mapping data is used to identify movements corresponding to pre-defined gestures using gesture filters. Detection of a viable gesture can trigger one or more user-interface actions or controls. Gesture modifiers are provided to modify the user-interface action triggered by detection of a gesture and/or to aid in the identification of gestures. | 11-24-2011 |
20110313768 | COMPOUND GESTURE-SPEECH COMMANDS - A multimedia entertainment system combines both gestures and voice commands to provide an enhanced control scheme. A user's body position or motion may be recognized as a gesture, and may be used to provide context to recognize user generated sounds, such as speech input. Likewise, speech input may be recognized as a voice command, and may be used to provide context to recognize a body position or motion as a gesture. Weights may be assigned to the inputs to facilitate processing. When a gesture is recognized, a limited set of voice commands associated with the recognized gesture are loaded for use. Further, additional sets of voice commands may be structured in a hierarchical manner such that speaking a voice command from one set of voice commands leads to the system loading a next set of voice commands. | 12-22-2011 |
20120089392 | SPEECH RECOGNITION USER INTERFACE - Speech recognition techniques are disclosed herein. In one embodiment, a novice mode is available such that when the user is unfamiliar with the speech recognition system, a voice user interface (VUI) may be provided to guide them. The VUI may display one or more speech commands that are presently available. The VUI may also provide feedback to train the user. After the user becomes more familiar with speech recognition, the user may enter speech commands without the aid of the novice mode. In this “experienced mode,” the VUI need not be displayed. Therefore, the user interface is not cluttered. | 04-12-2012 |
20120157208 | PERSISTENT HANDLES FOR INTERFACE GUIDES - A computing system translates a world space position of a hand of a human target to a screen space position of a user interface and locks the hand to a handle of the user interface if world space parameters of the hand overcome a grab threshold of the handle. When the hand is locked to the handle, the computing system translates a world space position of the hand to a screen space handle position that is constrained along one or more interface guides. The hand is unlocked from the handle at a release position of the handle if world space parameters of the hand overcome a release threshold of the handle. The handle is retained at the release position after the hand is unlocked from the handle. | 06-21-2012 |
20120327193 | VOICE-BODY IDENTITY CORRELATION - A system and method are disclosed for tracking image and audio data over time to automatically identify a person based on a correlation of their voice with their body in a multi-user game or multimedia setting. | 12-27-2012 |
20130027296 | COMPOUND GESTURE-SPEECH COMMANDS - A multimedia entertainment system combines both gestures and voice commands to provide an enhanced control scheme. A user's body position or motion may be recognized as a gesture, and may be used to provide context to recognize user generated sounds, such as speech input. Likewise, speech input may be recognized as a voice command, and may be used to provide context to recognize a body position or motion as a gesture. Weights may be assigned to the inputs to facilitate processing. When a gesture is recognized, a limited set of voice commands associated with the recognized gesture are loaded for use. Further, additional sets of voice commands may be structured in a hierarchical manner such that speaking a voice command from one set of voice commands leads to the system loading a next set of voice commands. | 01-31-2013 |
20130120254 | Two-Stage Swipe Gesture Recognition - Systems, methods and computer program products for facilitating the recognition of user air swipe gestures are disclosed. Such systems, methods and computer program products provide a two-stage gesture recognition approach that combines desirable aspects of object manipulation gestures and symbolic gestures in order to create an interaction that is both reliable and intuitive for users of a computing system. In a first position-based stage, the user moves the cursor into a swipe activation zone. Second, in a motion-based stage, the user swipes their hand from the activation zone past a swipe gate within a certain amount of time to complete the interaction. GUI feedback is provided following the first stage to let the user know that the swipe interaction is available, and after the second stage to let the user know that the swipe is completed. | 05-16-2013 |
20130125066 | Adaptive Area Cursor - Described is a technology by which a user's cursor movement is assisted to help select elements of a user interface that may be otherwise difficult to target. An area cursor is provided that may intersect more than one element. If so, a computation result (e.g., a percentage) is computed for each intersected element that is based upon intersection with the cursor and a total size of the element; the largest percentage intersection is selected. The computation (e.g., intersected area divided by total element area) favors smaller elements as they have a smaller area in the denominator. Also described is changing the cursor size to help hit elements and/or based upon one or more criteria. Still further described is determining the total size of an element based upon weighting, in addition to or instead of the element's actual size. Weighting may be based upon one or more criteria. | 05-16-2013 |
20130154958 | CONTENT SYSTEM WITH SECONDARY TOUCH CONTROLLER - A controller for a content presentation and interaction system which includes a primary content presentation device. The controller includes a tactile control input and a touch screen control input. The tactile control input is responsive to the inputs of a first user and communicatively coupled to the content presentation device. The controller a plurality of tactile input mechanisms and provides a first set of the plurality of control inputs manipulating content. The controller includes a touch screen control input responsive to the inputs of the first user and communicatively coupled to the content presentation device. The second controller is proximate the first controller and provides a second set of the plurality of control inputs. The second set of control inputs includes alternative inputs for at least some of the controls and additional inputs not available using the tactile input mechanisms. | 06-20-2013 |
20130159555 | INPUT COMMANDS - Input command techniques are described. In one or more implementations, a computing device processes one or more inputs that are received from one or more input sources to determine a command that corresponds to the one or more inputs. The command is exposed to one or more controls that are implemented as software that is executed on the computing device and that have subscribed to the command. | 06-20-2013 |
20130311944 | HANDLES INTERACTIONS FOR HUMAN-COMPUTER INTERFACE - A system is disclosed for providing on-screen graphical handles to control interaction between a user and on-screen objects. A handle defines what actions a user may perform on the object, such as for example scrolling through a textual or graphical navigation menu. Affordances are provided to guide the user through the process of interacting with a handle. | 11-21-2013 |
20130346875 | Personalized Interactive Entertainment Profile - Described is a technology by which an entity's (e.g., a user's or group's) usage of a digital entertainment service is used to automatically generate an interactive, personalized three-dimensional visualization representing the entity's career on a digital entertainment service. Usage events are collected as profile information, which is processed to generate the visualization, as well as to automatically theme the user's experience. Filtering and prioritization of data within the profile information is performed based on the predicted degree of interest to the entity and to others; the entity may provide preference data to vary the automatically generated visualization and/or theme. | 12-26-2013 |
20140207446 | INDEFINITE SPEECH INPUTS - Embodiments are disclosed that relate to the use of speech inputs including indefinite quantitative terms as computing device inputs. For example, one disclosed embodiment provides a method of operating a computing device, the method including receiving a speech input comprising an indefinite quantitative term, determining a definite quantity corresponding to the indefinite quantitative term, and applying the definite quantity to an action performed via the computing device in response to the speech input. | 07-24-2014 |
20140207452 | VISUAL FEEDBACK FOR SPEECH RECOGNITION SYSTEM - Embodiments are disclosed that relate to providing visual feedback in a speech recognition system. For example, one disclosed embodiment provides a method including displaying a graphical feedback indicator having a variable appearance dependent upon a state of the speech recognition system. The method further comprises receiving a speech input, modifying an appearance of the graphical feedback indicator in a first manner if the speech input is heard and understood by the system, and modifying the appearance of the graphical feedback indicator in a different manner than the first manner if the speech input is heard and not understood. | 07-24-2014 |
20140214415 | USING VISUAL CUES TO DISAMBIGUATE SPEECH INPUTS - Embodiments related to recognizing speech inputs are disclosed. One disclosed embodiment provides a method for recognizing a speech input including receiving depth information of a physical space from a depth camera, determining an identity of a user in the physical space based on the depth information, receiving audio information from one or more microphones, and determining a speech input from the audio input. If the speech input comprises an ambiguous term, the ambiguous term in the speech input is compared to one or more of depth image data received from the depth image sensor and digital content consumption information for the user to identify an unambiguous term corresponding to the ambiguous term. After identifying the unambiguous term, an action is taken on the computing device based on the speech input and the unambiguous term. | 07-31-2014 |
20150035750 | ERGONOMIC PHYSICAL INTERACTION ZONE CURSOR MAPPING - Users move their hands in a three dimensional (“3D”) physical interaction zone (“PHIZ”) to control a cursor in a user interface (“UI”) shown on a computer-coupled 2D display such as a television or monitor. The PHIZ is shaped, sized, and positioned relative to the user to ergonomically match the user's natural range of motions so that cursor control is intuitive and comfortable over the entire region on the UI that supports cursor interaction. A motion capture system tracks the user's hand so that the user's 3D motions within the PHIZ can be mapped to the 2D UI. Accordingly, when the user moves his or her hands in the PHIZ, the cursor correspondingly moves on the display. Movement in the z direction (i.e., back and forth) in the PHIZ allows for additional interactions to be performed such as pressing, zooming, 3D manipulations, or other forms of input to the UI. | 02-05-2015 |
20150039317 | SYSTEM WITH MULTIPLE SIMULTANEOUS SPEECH RECOGNIZERS - A speech recognition system interprets both spoken system commands as well as application commands. Users may speak commands to an open microphone of a computing device that may be interpreted by at least two speech recognizers operating simultaneously. The first speech recognizer interprets operating system commands and the second speech recognizer interprets application commands. The system commands may include at least opening and closing an application and the application commands may include at least a game command or navigation within a menu. A reserve word may be used to identify whether the command is for the operation system or application. A user's cadence may also indicate whether the speech is a global command or application command. A speech recognizer may include a natural language software component located in a remote computing device, such as in the so-called cloud. | 02-05-2015 |
20150097766 | ZOOMING WITH AIR GESTURES - An NUI system for mediating input from a computer-system user. The NUI system includes a logic machine and an instruction storage machine. The instruction-storage machine holds instructions that cause the logic machine to receive data tracking a change in conformation of the user including at least a hand trajectory of the user. If the data show increasing separation between two hands of the user, the NUI system causes a foreground process of the computer system to be displayed in greater detail on the display. If the data show decreasing separation between the two hands of the user, the NUI system causes the foreground process to be represented in lesser detail. | 04-09-2015 |
20150123890 | TWO HAND NATURAL USER INPUT - Embodiments are disclosed which relate to two hand natural user input. For example, one disclosed embodiment provides a method comprising receiving first hand tracking data regarding a first hand of a user and second hand tracking data regarding a second hand of the user from a sensor system. The first hand tracking data and the second hand tracking data temporally overlap. A gesture is then detected based on the first hand tracking data and the second hand tracking data, and one or more aspects of the computing device are controlled based on the gesture detected. | 05-07-2015 |
20150123901 | GESTURE DISAMBIGUATION USING ORIENTATION INFORMATION - Embodiments are disclosed that relate to controlling a computing device based upon gesture input. In one embodiment, orientation information of the human subject is received, wherein the orientation information includes information regarding an orientation of a first body part and an orientation of a second body part. A gesture performed by the first body part is identified based on the orientation information, and an orientation of the second body part is identified based on the orientation information. A mapping of the gesture to an action performed by the computing device is determined based on the orientation of the second body part. | 05-07-2015 |
20150135308 | CORRELATED DISPLAY OF BIOMETRIC IDENTITY, FEEDBACK AND USER INTERACTION STATE - Aspects of the subject disclosure are directed towards providing feedback to users of multi-user system that has biometric recognition capabilities, so that a user knows whether the system has correctly associated the user with his or her identity. The feedback may include a display of a current camera view, along with visible identity information that is associated with each user in the view. The feedback may include per-user icons (e.g., tiles, thumbnail images and so on) by which a user visually confirms that he or she is correctly recognized. Any misrecognition may be detected via the feedback and corrected. Feedback may convey other information, such as the current interaction state/capabilities of a user. | 05-14-2015 |
20150193107 | GESTURE LIBRARY FOR NATURAL USER INPUT - A method to decode natural user input from a human subject. The method includes detection of a gesture and concurrent grip state of the subject. If the grip state is closed during the gesture, then a user-interface (UI) canvas of the computer system is transformed based on the gesture. If the grip state is open during the gesture, then a UI object arranged on the UI canvas is activated based on the gesture. | 07-09-2015 |
20150193124 | VISUAL FEEDBACK FOR LEVEL OF GESTURE COMPLETION - Embodiments are disclosed that relate to providing feedback for a level of completion of a user gesture via a cursor displayed on a user interface. One disclosed embodiment provides a method comprising displaying a cursor having a visual property and moving a screen-space position of the cursor responsive to the user gesture. The method further comprises changing the visual property of the cursor in proportion to a level of completion of the user gesture. In this way, the level of completion of the user gesture may be presented to the user in a location to which the attention of the user is directed during performance of the gesture. | 07-09-2015 |
20150254057 | VOICE-COMMAND SUGGESTIONS - The identity of a user interacting with a computing system a computing system is determined, and a voice command is selected from a set of voice commands based on the user identity. A voice-command suggestion corresponding to the voice command is selected and presented via a display. | 09-10-2015 |
20150254058 | VOICE CONTROL SHORTCUTS - A contextual state of a graphical user interface presented via a display of the computing system is identified. A voice command is selected from a set of voice commands based on the contextual state of the graphical user interface. A context-specific voice-command suggestion corresponding to the selected voice command is identified. A graphical user interface including the context-specific voice-command suggestion is presented via a display. | 09-10-2015 |
20150256873 | RELAYED VOICE CONTROL OF DEVICES - Voice input is received, via a microphone. The voice input is translated into a machine-understandable representation of the voice input. An operation performable by an audio/video device and corresponding to the machine-understandable representation of the voice input is selected. A signal code for the operation is broadcast, via a broadcast device, in a format recognizable by the audio/video device. | 09-10-2015 |
20150298010 | BROADCAST INITIATION WITHOUT INTERRUPTION TO ACTIVE GAMEPLAY - A video game application is executed on a computer gaming device. While the video game application is providing active gameplay, the computer gaming device receives a command to broadcast the active gameplay. Responsive to the command, the computer gaming device broadcasts the active gameplay without interrupting the active gameplay. | 10-22-2015 |
Patent application number | Description | Published |
20100254988 | Bispecific Anti ErbB2 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-07-2010 |
20100254989 | Bispecific Anti ErbB1 / Anti c Met Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-07-2010 |
20100316645 | Bispecific Antigen Binding Proteins - The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-16-2010 |
20100322934 | Bispecific, Tetravalent Antigen Binding Proteins - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-23-2010 |
20100322935 | Tri- or Tetraspecific Antibodies - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 12-23-2010 |
20110165151 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine. | 07-07-2011 |
20110165152 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 07-07-2011 |
20110236388 | BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 09-29-2011 |
20110293613 | BISPECIFIC ANTIBODIES - The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-01-2011 |
20120039807 | Anti-Tenascin-C A2 Antibodies and Methods of Use - The invention provides antibodies against the A2 domain of tenascin-C and methods of using the same. | 02-16-2012 |
20120128591 | ANTI-FAP ANTIBODIES AND METHODS OF USE - The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same. | 05-24-2012 |
20120134990 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody. | 05-31-2012 |
20120237506 | Antigen Binding Proteins - The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof. | 09-20-2012 |
20120237507 | Monovalent Antigen Binding Proteins - The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 09-20-2012 |
20120244112 | MUTANT INTERLEUKIN-2 POLYPEPTIDES - The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof. | 09-27-2012 |
20120258073 | IMMUNOTHERAPY - The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them. | 10-11-2012 |
20120263713 | Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 10-18-2012 |
20120276085 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent. | 11-01-2012 |
20120276125 | NOVEL IMMUNOCONJUGATES - The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease. | 11-01-2012 |
20120309016 | 3D ADCC NK FACS ASSAY - Herein is reported a cell analytical technology based on a three-dimensional spheroid/aggregate co-culture assay, wherein the spheroid or aggregate is formed of tumor and natural killer cells. This method is useful for the in vitro functional analysis of antibodies in single and high-throughput format. | 12-06-2012 |
20120315268 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Lyl antibody and bendamustine. | 12-13-2012 |
20130022601 | TRIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 01-24-2013 |
20130058936 | BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE - The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-07-2013 |
20130058937 | Bispecific antigen binding molecules - The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-07-2013 |
20130060011 | FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE - The present invention relates to bispecific antibodies comprising at least two fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-07-2013 |
20130078249 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-28-2013 |
20130078250 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-28-2013 |
20130156772 | Bispecific Anti ErbB1 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 06-20-2013 |
20130183290 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODY - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly | 07-18-2013 |
20130195846 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody. | 08-01-2013 |
20130273054 | Bispecific Anti ErbB2/Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-17-2013 |
20130280243 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus. | 10-24-2013 |
20130288266 | DETECTION OF A POSTTRANSLATIONALLY MODIFIED POLYPEPTIDE BY A BI-VALENT BINDING AGENT - A bi-valent binding agent having a first monovalent binder that binds to a polypeptide epitope of a target polypeptide, a second monovalent binder that binds to a posttranslational polypeptide modification on the target polypeptide and a linker. Further disclosed are methods for the detection of a posttranslationally modified target polypeptide, for making the disclosed bi-valent binding agent, and for use of the disclosed bi-valent binding agent in histological staining procedures. | 10-31-2013 |
20130302274 | COMBINATION THERAPY - The present invention is directed to the combination therapy of an afucosylated antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer. | 11-14-2013 |
20130336972 | RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC - The present invention relates to DCC-fusion proteins, nucleic acid molecules encoding the DCC-fusion proteins, as well as methods for their production and their use in treatment of cancer such as colorectal cancer, NSCLC and metastatic breast cancer. The present invention also relates to methods of treating cancer such as colorectal cancer, NSCLC and metastatic breast cancer by administering DCC-fusion proteins. | 12-19-2013 |
20140004104 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | 01-02-2014 |
20140017244 | Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases - The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 01-16-2014 |
20140044675 | INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF - The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease. | 02-13-2014 |
20140044705 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine. | 02-13-2014 |
20140065097 | Immunotherapy - The present invention provides combinations of (a) an immunoconjugate comprising at least one antigen-binding moiety and an effector moiety, and (b) an antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them. | 03-06-2014 |
20140065707 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-06-2014 |
20140072528 | IMMUNOTHERAPY - The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them. | 03-13-2014 |
20140120613 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to a host cell for use in the expression of a novel domain exchanged, bivalent, bispecific antibody. | 05-01-2014 |
20140135482 | Bispecific Anti ErbB3 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-3 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 05-15-2014 |
20140140988 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A MDM2 INHIBITOR - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a MDM2 inhibitor. | 05-22-2014 |
20140193415 | BISPECIFIC ANTI-EGFR/ANTI IGF-1R ANTIBODIES - The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 07-10-2014 |
20140242079 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 08-28-2014 |
20140242080 | BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES - The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 08-28-2014 |
20140294807 | COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES - The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody. | 10-02-2014 |
20140322200 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODY - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody. | 10-30-2014 |
20140356352 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate. | 12-04-2014 |
20140370019 | BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5, ANTIBODIES SPECIFIC FOR DR5 AND METHODS OF USE - The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-18-2014 |
20150030598 | TRI- OR TETRASPECIFIC ANTIBODIES - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 01-29-2015 |
20150044214 | BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 02-12-2015 |
20150056186 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent. | 02-26-2015 |
20150071911 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus. | 03-12-2015 |
20150079023 | COMBINATION THERAPY - The present invention is directed to the combination therapy of an afucosylated antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer. | 03-19-2015 |
20150079073 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 03-19-2015 |
20150093376 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine. | 04-02-2015 |
20150125446 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITOR - The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor. | 05-07-2015 |
20150191535 | BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG2 ANTIBODIES - The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 07-09-2015 |
20150218260 | INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF - The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). More particularly, the invention concerns fusion proteins of immunoglobulins and mutant IL-2 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of autoimmune diseases and immune-mediated inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease. | 08-06-2015 |
20150232548 | Combination therapy with an anti-ANG2 antibody and a CD40 agonist - The present invention relates to the combination therapy of an antibodies that binds to human angiopoietin 2 (ANG-2) with a CD40 agonist. | 08-20-2015 |
20150265703 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus. | 09-24-2015 |
20150274834 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 10-01-2015 |
20150274845 | BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE - The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-01-2015 |
20150284457 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-08-2015 |